Alex Fergus - Light Therapy Insiders
My name is Alex Fergus, and I'm a health and technology geek providing in-depth, independent product reviews on the latest red light therapy devices. With over seven years of experience studying light therapy and having used and tested dozens of hundreds of light therapy products, you can be sure that I'll have a video to help you with your educational or product-buying needs. Test, review, compare, and study all things Red Light Therapy.
Whether you're seeking out the best Red Light Body Panel or an LED Mask or simply trying to learn more about the complexities of Red Light, my YouTube channel has videos for you. https://www.youtube.com/@AlexFergusdotcom
I hope you enjoy and find my podcasts beneficial!
Alex
Alex Fergus - Light Therapy Insiders
THIS Device Counters MCI/Alzheimer - Here’s The Data
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Photobiomodulation for the brain is getting serious scientific attention, especially for mild cognitive impairment (MCI) and early Alzheimer’s risk.
In this episode of Light Therapy Insiders, Bart Wolbers speaks with Dr. Neda Rashini, a physician-scientist focused on neurodegenerative research, about transcranial photobiomodulation, pilot trial results, mitochondrial biomarkers, inflammation, brain connectivity, and why this field may become an important part of future brain-health treatment plans.
Show Notes
In this episode, Dr. Neda Rashini explains how she went from being skeptical of photobiomodulation to leading clinical research on its use in people with mild cognitive impairment. The conversation covers why MCI matters, how placebo-controlled PBM trials are designed, what biomarkers were measured, and which outcomes looked promising in her pilot trial. They also discuss side effects, responder variability, and why bigger studies are still needed before stronger conclusions can be made.
Key Topics
Why Dr. Neda Rashini became interested in transcranial photobiomodulation
Although photobiomodulation has been around for decades, it has only recently gained traction in neuroscience research. Dr. Neda Rashini shares how her initial skepticism led her to investigate whether the biological claims behind PBM could actually be measured in clinical research.
Why mild cognitive impairment matters
MCI is often one of the earliest diagnosable stages before Alzheimer’s dementia develops. Dr. Neda Rashini explains why this stage may be a better window for intervention than later-stage disease, when neuronal loss may already be too advanced.
How the pilot trial was designed
The study compared an active transcranial photobiomodulation device against a sham device in people with MCI. Participants used what appeared to be the same headset, but only the active group received the full PBM treatment.
The biomarkers researchers measured
The trial looked beyond cognition alone. Dr. Neda Rashini’s team assessed mitochondrial biomarkers, inflammatory markers, functional brain connectivity, brain metabolites, and cognitive outcomes to better understand possible mechanisms.
What improved in the pilot study
The active group showed improved general cognition and recognition memory compared with the sham group. Researchers also observed changes in the lactate-to-pyruvate ratio, a reduction in IL-6 levels, and increased functional connectivity within the default mode network.
What did not significantly change
Not every marker moved. Some inflammation markers and neurodegeneration markers did not show significant differences, which Dr. Na says i
Thanks for listening!
Disclaimer: Information shared is not medical advice.
For the latest discounts, please visit my website: https://www.lighttherapyinsiders.com/red-light-therapy-discount-codes-deals-recommendations/
· Check out my YouTube Channel for product reviews and all things red light therapy!
· Check out my website for research articles, reviews, and more on light therapy
· Join my Facebook group with almost 10K members; it's an interactive group sharing their experiences.